Welcome to our dedicated page for eXoZymes news (Ticker: EXOZ), a resource for investors and traders seeking the latest updates and insights on eXoZymes stock.
eXoZymes Inc (EXOZ) pioneers AI-driven biomanufacturing using engineered enzymes to produce sustainable biochemicals for pharmaceuticals, biofuels, and cosmetics. This page serves as the definitive source for official company announcements and industry analysis.
Access real-time updates on EXOZ's financial results, strategic partnerships, and technological breakthroughs. Our curated repository includes earnings reports, product launch details, regulatory milestones, and executive commentary – all essential for evaluating the company's position in synthetic biology and green chemistry.
Key coverage areas include enzyme optimization advancements, bioreactor scaling initiatives, and sustainable feedstock partnerships. Investors gain critical insights into how EXOZ's platform addresses global demand for eco-friendly chemical alternatives.
Bookmark this page for streamlined tracking of EXOZ's progress in replacing petrochemical processes with precision biosolutions. Regularly updated to reflect the company's evolving role in industrial biotechnology.
eXoZymes (NASDAQ:EXOZ) reported a successful 100× scale-up of its N-trans-caffeoyltyramine (NCT) production using its cell-free, exozyme-based biomanufacturing platform on December 11, 2025. The scaled run delivered >99% conversion from feedstock to product and was executed under partner-operated conditions by Cayman Chemical, demonstrating process transferability and robustness. eXoZymes said downstream isolation and full data analysis are ongoing, with additional technical details expected in early 2026.
eXoZymes (NASDAQ:EXOZ) will host a Q3 2025 operational update webinar at 5:00 PM ET on November 13, 2025 covering results through the quarter ended October 31, 2025. Management will review commercialization progress, recent hires, and near-term milestones.
Q3 highlights: net loss of $2.29 million (quarter), year-to-date loss of $6.5 million, operating expenses up $0.9 million versus prior year, and $5.1 million cash on hand, described as supporting operations into early Q2 2026. Company named Amy Lunzer chief of staff and promoted co-founder Tyler Korman, PhD to chief scientific officer. A recording and live webcast will be available on investor relations.
eXoZymes (NASDAQ:EXOZ) announced leadership changes effective November 13, 2025: co-founder Tyler Korman, PhD, is appointed Chief Scientific Officer and Amy Lunzer is named Chief of Staff. Korman will lead scientific strategy after roles from Director of R&D to VP of Research and says the company aims to scale AI-enhanced enzyme biomanufacturing for nutraceuticals and pharmaceuticals. Lunzer brings business, supply-chain, and operations experience. Management changes take effect immediately and will be discussed on the company’s 2025 Q3 update call at 5:00 PM ET.
eXoZymes (NASDAQ:EXOZ) will host a Third Quarter 2025 update webinar on Thursday, November 13, 2025 at 5:00 PM ET.
CEO Michael Heltzen and select management will review Q3 2025 developments, ongoing initiatives, anticipated milestones, and hold a Q&A for investors. Investors can pre-register and access the live webinar via the company’s investor relations website at https://exozymes.com/investor#webinar.
eXoZymes (NASDAQ:EXOZ) announced that CEO Michael Heltzen will participate on the panel "AI's Billion-dollar Bet on Life Sciences: From Drug Discovery to Patient Impact" at Beryl Elites' 7th Annual Investment Conference in New York City on November 4, 2025.
The company describes a next‑generation, cell‑free biomanufacturing platform that uses AI to engineer enzymes called exozymes, enabling enzyme pathways outside living cells. Management cites a flagship molecule, NCT, positioned as a metabolism‑boosting product. The panel runs 10:50–11:40 AM ET and will cover AI applications in drug discovery, biases, regulation, and scaling.
eXoZymes (NASDAQ:EXOZ) announced that CEO Michael Heltzen will present at the Spartan Capital Securities Second Annual Investor Conference on November 3, 2025 at the Marriott Marquis Hotel in New York City.
The 15-minute presentation is scheduled for 11:20–11:35 AM at Track 4 and will cover the company’s AI‑engineered, cell‑free biomanufacturing platform and its flagship small molecule product, NCT, aimed at metabolic and gut‑health markets.
eXoZymes (NASDAQ:EXOZ) announced that CEO Michael Heltzen will present at the ThinkEquity Annual Investor Conference on October 30, 2025 at the Mandarin Oriental Hotel in New York City.
The 30-minute presentation is scheduled for 8:00–8:30 AM in Lotus Suite East and will describe eXoZymes' AI-engineered enzyme platform—branded exozymes—which the company says enables cell-free, scalable biomanufacturing for natural products and potential pharmaceuticals. Management highlights a natural product called NCT that is reported to be showing promising results in improving metabolic health.
ThinkEquity expects over 750 institutional and high-net-worth investors and more than 85 selected companies to attend the conference.
eXoZymes (NASDAQ:EXOZ), a pioneer in AI-engineered enzymes for sustainable biomanufacturing, announced key leadership appointments to BioMADE Governance Committees. CCO Damien Perriman has been elected to the BioMADE Leadership Council, while VP of Development Dr. Paul Opgenorth joins the Technical Committee.
These appointments position eXoZymes as a thought leader in cell-free biomanufacturing, with both executives set to influence national priorities and technical roadmaps through BioMADE, a federally funded Manufacturing Innovation Institute. Dr. Opgenorth brings additional expertise from his role as PI in the NSF's CFIRE program and BioMADE 4.0 project.
eXoZymes (NASDAQ:EXOZ), a pioneer in AI-engineered enzymes, announced its Q2 2025 financial results and operational highlights. The company secured a significant role in a $9M NSF-funded initiative, receiving a $3M share to develop cell-free biomanufacturing solutions. The quarter saw increased operating expenses of $1.20M and a net loss of $2.36M.
Notable achievements include a breakthrough in gram-scale NCT production with 96% yield and 99% purity. The company ended Q2 with $6.99M in cash, sufficient to fund operations through Q1 2026. Management will discuss these results and future outlook in today's earnings call at 5:00 PM ET.
eXoZymes (NASDAQ:EXOZ), a company specializing in AI-engineered enzymes for sustainable feedstock transformation, has announced its upcoming Q2 2025 earnings webinar. The event will take place on Tuesday, August 12, 2025, at 5:00 PM ET.
CEO Michael Heltzen and management team members will discuss quarterly results, recent developments, ongoing initiatives, and future milestones. The presentation will include a Q&A session. Investors can pre-register for the webinar or access it through the company's investor relations website on the day of the event.
FAQ
What is the current stock price of eXoZymes (EXOZ)?
What is the market cap of eXoZymes (EXOZ)?
